NuPathe Announces Allowance of Additional U.S. Patent Application for NP202
NuPathe Inc. (NASDAQ: PATH), a biopharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application 11/195,845 titled "Drug Containing Implants and Methods of Use Thereof." The allowed claims relate to a rod-shaped implant or structure that delivers therapeutic levels of risperidone for 20 to 190 days as well as to methods for treating medication noncompliance-associated diseases including schizophrenia and bipolar disorder. Given this action, NuPathe expects the patent to issue within the next few months. Once issued, it will provide patent protection through December 2027 for NP202, NuPathe's long-term biodegradable risperidone implant for the treatment of schizophrenia and bipolar disorder. NuPathe has a portfolio of additional licensed patent applications pending in the U.S. and other territories for NP202.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.